$PLX
Protalix BioTherapeutics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000155837020011974 Filed on October 29, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $19.50M $10.79M $17.76M
YoY Change 9.8% -24.27% 71.59%
Cost Of Revenue $2.750M $2.868M $2.950M
YoY Change -6.78% -10.51% 29.39%
Gross Profit $16.74M $7.922M $14.81M
YoY Change 13.03% -28.26% 83.29%
Gross Profit Margin 85.85% 73.42% 83.39%
Selling, General & Admin $2.950M $2.816M $3.010M
YoY Change -1.99% 8.85% 38.71%
% of Gross Profit 17.62% 35.55% 20.32%
Research & Development $10.95M $7.688M $9.620M
YoY Change 13.83% -23.12% -3.51%
% of Gross Profit 65.41% 97.05% 64.96%
Depreciation & Amortization $290.0K $300.0K $410.0K
YoY Change -29.27% -30.23% 0.0%
% of Gross Profit 1.73% 3.79% 2.77%
Operating Expenses $13.91M $10.50M $12.61M
YoY Change 10.31% -16.55% 7.32%
Operating Profit $2.830M -$2.582M $2.200M
YoY Change 28.64% 67.23% -159.95%
Interest Expense -$2.440M -$1.860M -$1.910M
YoY Change 27.75% -7.92% 8.52%
% of Operating Profit -86.22% -86.82%
Other Income/Expense, Net -$1.855M
YoY Change -7.99%
Pretax Income $400.0K -$4.440M $290.0K
YoY Change 37.93% 24.72% -105.34%
Income Tax
% Of Pretax Income
Net Earnings $400.0K -$4.437M $290.0K
YoY Change 37.93% 24.63% -105.34%
Net Earnings / Revenue 2.05% -41.12% 1.63%
Basic Earnings Per Share -$0.14
Diluted Earnings Per Share $0.01 -$0.14 $0.02
COMMON SHARES
Basic Shares Outstanding 33.34M 32.86M
Diluted Shares Outstanding 32.86M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.30M $13.50M $17.80M
YoY Change 2.81% -36.92% -52.91%
Cash & Equivalents $18.27M $13.53M $17.79M
Short-Term Investments
Other Short-Term Assets $2.096M $2.612M $1.832M
YoY Change 14.41% -6.71% -2.4%
Inventory $13.08M $13.28M $8.155M
Prepaid Expenses $841.0K $314.0K
Receivables $2.000M $3.146M $4.700M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $55.72M $60.33M $32.48M
YoY Change 71.57% 49.34% -38.7%
LONG-TERM ASSETS
Property, Plant & Equipment $4.845M $4.639M $5.273M
YoY Change -8.12% -58.95% -17.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $1.600M $2.000M
YoY Change -10.0% -20.0% 11.11%
Total Long-Term Assets $12.21M $11.98M $12.91M
YoY Change -5.44% -9.94% 58.48%
TOTAL ASSETS
Total Short-Term Assets $55.72M $60.33M $32.48M
Total Long-Term Assets $12.21M $11.98M $12.91M
Total Assets $67.93M $72.31M $45.39M
YoY Change 49.66% 34.66% -25.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.93M $8.400M $11.91M
YoY Change 16.98% 7.69% 15.88%
Accrued Expenses $9.586M $1.200M $7.360M
YoY Change 30.24% 0.0% 15.58%
Deferred Revenue $5.394M $16.72M $16.34M
YoY Change -66.98% 65.54%
Short-Term Debt $4.100M $4.300M $4.300M
YoY Change -4.65%
Long-Term Debt Due $54.40M
YoY Change
Total Short-Term Liabilities $86.47M $43.90M $40.18M
YoY Change 115.24% 31.82% 58.46%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $53.60M $51.50M
YoY Change -99.81% -3.42% -3.38%
Other Long-Term Liabilities $51.00K $46.00K $509.0K
YoY Change -89.98% -99.87% -90.38%
Total Long-Term Liabilities $8.497M $61.73M $75.54M
YoY Change -88.75% -32.31% -14.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $86.47M $43.90M $40.18M
Total Long-Term Liabilities $8.497M $61.73M $75.54M
Total Liabilities $94.97M $105.6M $115.7M
YoY Change -17.93% -15.23% 1.49%
SHAREHOLDERS EQUITY
Retained Earnings -$347.4M -$340.8M
YoY Change 1.91% 5.67%
Common Stock $320.3M $270.5M
YoY Change 18.41% 0.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$27.04M -$33.32M -$70.32M
YoY Change
Total Liabilities & Shareholders Equity $67.93M $72.31M $45.39M
YoY Change 49.66% 34.66% -25.75%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income $400.0K -$4.437M $290.0K
YoY Change 37.93% 24.63% -105.34%
Depreciation, Depletion And Amortization $290.0K $300.0K $410.0K
YoY Change -29.27% -30.23% 0.0%
Cash From Operating Activities -$7.550M -$3.610M -$3.690M
YoY Change 104.61% 12.11% -7.75%
INVESTING ACTIVITIES
Capital Expenditures $280.0K $100.0K $30.00K
YoY Change 833.33% -74.36% -84.21%
Acquisitions
YoY Change
Other Investing Activities $7.860M $7.910M $50.00K
YoY Change 15620.0% -15920.0% -82.14%
Cash From Investing Activities $7.590M $7.810M $30.00K
YoY Change 25200.0% -1875.0% -66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.650M 4.480M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -7.550M -3.610M -3.690M
Cash From Investing Activities 7.590M 7.810M 30.00K
Cash From Financing Activities 4.650M 4.480M 0.000
Net Change In Cash 4.690M 8.680M -3.660M
YoY Change -228.14% -337.16% -6.39%
FREE CASH FLOW
Cash From Operating Activities -$7.550M -$3.610M -$3.690M
Capital Expenditures $280.0K $100.0K $30.00K
Free Cash Flow -$7.830M -$3.710M -$3.720M
YoY Change 110.48% 2.77% -11.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33357
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Snunit Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Science Park
dei Entity Address Address Line3
EntityAddressAddressLine3
POB 455
dei Entity Address City Or Town
EntityAddressCityOrTown
Carmiel
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
2161401
dei City Area Code
CityAreaCode
972-4
dei Local Phone Number
LocalPhoneNumber
988-9488
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 par value,
dei Trading Symbol
TradingSymbol
PLX
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33336709
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13533000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17792000
CY2020Q3 plx Short Term Bank Deposits
ShortTermBankDeposits
27760000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3146000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4700000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2612000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1832000
CY2020Q3 us-gaap Inventory Net
InventoryNet
13281000
CY2019Q4 us-gaap Inventory Net
InventoryNet
8155000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
60332000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5700000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5677000
CY2020Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
11978000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12913000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
32479000
CY2020Q3 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1639000
CY2019Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1963000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4639000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5273000
CY2020Q3 us-gaap Assets
Assets
72310000
CY2019Q4 us-gaap Assets
Assets
45392000
CY2020Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
8351000
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6495000
CY2020Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
13347000
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
11905000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1176000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1139000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16720000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16335000
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
4301000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4301000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
43895000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40175000
CY2020Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
53505000
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
50957000
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1533000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16980000
CY2020Q3 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2088000
CY2019Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2565000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4558000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4528000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
509000
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
61730000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
75539000
CY2020Q3 us-gaap Liabilities
Liabilities
105625000
CY2019Q4 us-gaap Liabilities
Liabilities
115714000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-33315000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70322000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72310000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45392000
us-gaap Revenues
Revenues
43403000
us-gaap Revenues
Revenues
36934000
CY2020Q3 us-gaap Revenues
Revenues
10790000
CY2019Q3 us-gaap Revenues
Revenues
14248000
us-gaap Cost Of Revenue
CostOfRevenue
8121000
us-gaap Cost Of Revenue
CostOfRevenue
7945000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
2868000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
3205000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27214000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35021000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7688000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10000000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8197000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6885000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2816000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2587000
us-gaap Operating Income Loss
OperatingIncomeLoss
-129000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12917000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2582000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1544000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7150000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
5877000
CY2020Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1973000
CY2019Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2050000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
359000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
227000
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
118000
CY2019Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
34000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6791000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5650000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1855000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2016000
us-gaap Net Income Loss
NetIncomeLoss
-6920000
us-gaap Net Income Loss
NetIncomeLoss
-18567000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4437000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-3560000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27758104
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14838213
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32863788
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14838213
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-52881000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000
us-gaap Net Income Loss
NetIncomeLoss
-18567000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-70849000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70322000
plx Issuance Of Common Stock And Warrants Net Of Issuance Cost Value
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
41343000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1607000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
505000
plx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
472000
us-gaap Net Income Loss
NetIncomeLoss
-6920000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-33315000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-67485000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
196000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-3560000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-70849000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-34764000
CY2020Q3 plx Receivables Payments From Sale Of Common Stock And Warrants
ReceivablesPaymentsFromSaleOfCommonStockAndWarrants
4000000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
909000
CY2020Q3 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
505000
CY2020Q3 plx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
472000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4437000
plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
41343000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
472000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41815000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-33315000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
us-gaap Net Income Loss
NetIncomeLoss
-6920000
us-gaap Net Income Loss
NetIncomeLoss
-18567000
us-gaap Share Based Compensation
ShareBasedCompensation
2112000
us-gaap Share Based Compensation
ShareBasedCompensation
599000
us-gaap Depreciation
Depreciation
1011000
us-gaap Depreciation
Depreciation
1205000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
284000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-371000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-488000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
51000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
11000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2548000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2197000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15062000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2697000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-783000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4767000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-53000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
92000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5126000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1044000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3291000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4905000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-463000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
80000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18556000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15671000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
27500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
380000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
599000
plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
4000
plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
254000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-340000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
59000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27544000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-912000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
26000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
217000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4259000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16366000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17792000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37808000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13533000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21442000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
95000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
14000
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3941000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3607000
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2782000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
552000
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6558000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3996000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
564000
CY2020Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
41300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7826946
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21405733
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7854729
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26905842
CY2020Q3 us-gaap Inventory Net
InventoryNet
13281000
CY2019Q4 us-gaap Inventory Net
InventoryNet
8155000
CY2020Q1 plx Non Refundable Payment
NonRefundablePayment
1000000.0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.59
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8051
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.00365
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
4300000
CY2020Q3 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-430000

Files In Submission

Name View Source Status
0001558370-20-011974-index-headers.html Edgar Link pending
0001558370-20-011974-index.html Edgar Link pending
0001558370-20-011974.txt Edgar Link pending
0001558370-20-011974-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20200930.xsd Edgar Link pending
plx-20200930x10q.htm Edgar Link pending
plx-20200930x10q005.jpg Edgar Link pending
plx-20200930x10q006.jpg Edgar Link pending
plx-20200930x10q_htm.xml Edgar Link completed
plx-20200930xex31d1.htm Edgar Link pending
plx-20200930xex31d2.htm Edgar Link pending
plx-20200930xex32d1.htm Edgar Link pending
plx-20200930xex32d2.htm Edgar Link pending
plx-20200930_cal.xml Edgar Link unprocessable
plx-20200930_def.xml Edgar Link unprocessable
plx-20200930_lab.xml Edgar Link unprocessable
plx-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending